3 / 7
Notes:
Page 67
February 15-16, 2019 Amsterdam| Netherlands
Vascular Dementia
11
th
International Conference on
Volume 09
Vascular Dementia 2019
Journal of Alzheimers Disease & Parkinsonism | ISSN : 2161-0460
D-AAAP – Development of android assistive toolkit for Alzheimer’s patients and caregivers
Gaurav Gupta
Shoolini University, India
A
lzheimer’s disease, a common form of dementia causes deterioration of cognitive abilities of an individual which results in
difficulty in carrying out their routine activities. Research suggests that there is no cure for this deadly disease. However, the
progression of the disease can be slowed down by improving the patient’s quality of life, providing a solution for enhancing the
cognitive abilities of the patient. One of the possible solutions is to motivate the use of smartphone by the patient. Smartphones
play a crucial role for the family members of the Alzheimer’s patients as it helps the patients in carrying out their routine activities
by providing time to time notifications about them. Furthermore, the smartphone also helps in assisting the caregiver to take proper
care of the patient, such as retrieving the GPS locations of the patient, using Geotagging. Photographs can be used as a source of
the medium in helping patients remember their family members. They are susceptible to music; therefore, the patient brain can be
stimulated by playing their beloved tones. Smartphones tend to be a one-stop shop for providing all these facilities to the patients.
This motivates the need to build relatively simple cross-platform mobile applications with interactive GUIs, so as to enhance their
cognitive abilities. We are developing an android based mobile application comprising the features such as learning, caregiving,
pillbox, schedule, doctor dairy, news, family, music, Mapigate, social media, remember to work games safe zone. Finally, this
application shall be tested based on the current software testing trends and technologies following its testing for real time scenarios
by asking Alzheimer’s patients to use this application, thereby verifying and examining its efficiency and ease.
J Alzheimers Dis Parkinsonism 2019, Volume 09
DOI: 10.4172/2161-0460-C1-061
Multitarget therapies in the context of the aged associated oxidative stress induced cellular and subcellular and
vascular hypoperfusion and mitochondrial DNAdeletion during the development and maturation of Alzheimer
disease: past, present and future
Gjumrakch Aliev
1, 2, 3
1
“GALLY” International Biomedical Research Institute Inc., USA
2
University of Atlanta, Atlanta, USA
3
Russian Academy of Sciences, Russia
S
troke and arteriosclerosis with neurological consequences such as Alzheimer disease (AD) are two leading causes of age-
associated disability, dementia, and death. AD is now the sixth-leading cause of death in the United States. In the US, AD is
estimated to affect 4 million people (rising steeply from <1% of the population aged 65 to 40% of those aged 90) and costs $600
billion per year, which is equivalent to the total cost of stroke, heart disease, and cancer combined. Overall, there are no effective
strategies for determining and controlling this devastating disease. Because AD is a multifactorial pathology and the development of
new multitarget neuroprotective drugs is promising and attractive.